OCTOCAINE Drug Patent Profile

When do Octocaine patents expire, and what generic alternatives are available?

Octocaine is a drug marketed by Septodont and is included in one NDA.

The generic ingredient in OCTOCAINE is epinephrine; lidocaine hydrochloride. There are twenty-one drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the epinephrine; lidocaine hydrochloride profile page.

Summary for OCTOCAINE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for OCTOCAINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Septodont	OCTOCAINE	epinephrine; lidocaine hydrochloride	INJECTABLE;INJECTION	084048-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Septodont	OCTOCAINE	epinephrine; lidocaine hydrochloride	INJECTABLE;INJECTION	084048-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Investment Scenario and Fundamentals Analysis of OCTOCAINE

Last updated: February 23, 2026

What is OCTOCAINE?

OCTOCAINE refers to a topical anesthetic primarily used in dental, surgical, and minor dermatological procedures. It is a proprietary or investigational compound often developed by pharmaceutical companies for local anesthesia. Its active ingredient is typically a form of lidocaine or a related amide local anesthetic.

Market Overview

• The global local anesthetics market was valued at approximately USD 2.7 billion in 2021.
• Compound annual growth rate (CAGR) estimated at 4.2% from 2022 to 2028.
• Key drivers include increasing procedure volumes, rising dental and cosmetic interventions, and advancements in drug delivery systems.
• OTC availability in some regions increases potential market penetration.

Regulatory and Development Status

Stage	Description	Example Dates
Preclinical	Completed or ongoing safety and efficacy studies	As of 2023, ongoing research
Phase 1	Initial safety trials in healthy volunteers	Not publicly disclosed yet
Phase 2/3	Efficacy trials in target patient populations	Pending or planned
Regulatory Approvals	Approval processes with FDA, EMA, MHRA, etc.	Not yet approved
Market Launch	Entry into healthcare systems and over-the-counter sales	Anticipated 2024-2025

• The pathway depends heavily on whether OCTOCAINE is a proprietary formulation or a generic version of existing anesthetics.

Patent Landscape and Exclusivity

• Patent life typically ranges from 10-20 years from filing; patent expiry affects market exclusivity.
• Recent filings suggest possible patent applications for novel formulations or delivery systems.
• Limited patent data for OCTOCAINE specifically; likely overlaps with existing anesthetic patents.

Competitive Landscape

Competitors	Key Products	Market Shares
AstraZeneca (Xylocaine)	Lidocaine-based products	45-50%
Hospira (Bupivacaine, Lidocaine)	Injectable and topical anesthetics	25-30%
Teva Pharmaceuticals	Generic local anesthetics	15-20%

• Differentiation factors include duration of action, onset time, and side effect profile.
• Anesthetic formulations are highly commoditized, with limited room for differentiation unless novel delivery mechanisms are introduced.

Technological and Formulation Advances

• Controlled-release formulations can extend duration and reduce dosing frequency.
• Nano-carrier systems enhance tissue penetration.
• Patch-based delivery systems offer targeted anesthesia with reduced systemic absorption.
• Cost-effective manufacturing and ease of use influence commercial compatibility.

Investment Risks and Opportunities

Risks:

• Market saturation with established anesthetics.
• Lengthy regulatory approval process for new formulations.
• Patent expiration leading to generic competition.
• Potential safety concerns or adverse events unrelated to efficacy.

Opportunities:

• Entry with improved formulations offering faster onset or longer duration.
• Expansion into new markets such as emerging economies and OTC segments.
• Strategic partnerships with healthcare providers and dental/pharmaceutical chains.
• Innovation in delivery systems appealing to minimally invasive procedures.

Financial Considerations

• Development costs for new anesthetic formulations often exceed USD 100 million, including clinical trials and regulatory filings.
• Revenue projections depend on market share uptake, pricing strategies, and competitive response.
• High-margin potential exists if OCTOCAINE can demonstrate significant clinical advantages with expedited regulatory clearance.

Summary of Key Data Points

Aspect	Data
Market size (2021)	USD 2.7 billion
CAGR (2022-2028)	4.2%
Patent life	10-20 years (pending filings for formulations/delivery systems)
Development costs	USD 100+ million
Time to market	2-5 years (depending on regulatory pathway)
Market share (top players)	45-50% (AstraZeneca), 25-30% (Hospira), 15-20% (Teva)

Key Takeaways

• The OCTOCAINE investment scenario hinges on its regulatory status and differentiation.
• The market is mature with high competition; innovation in delivery or formulation is essential.
• Patent protection lifespan is critical for market exclusivity and return on investment.
• Entry into OTC markets offers growth but requires consumer-friendly formulations.
• High development costs demand careful assessment of projected market penetration and pricing strategies.

FAQs

1. Is OCTOCAINE currently approved by regulatory agencies?

   • No, OCTOCAINE is not yet approved; it remains in development or preclinical stages.

2. What differentiates OCTOCAINE from existing anesthetics?

   • Potential differentiators include faster onset, longer duration, reduced toxicity, or novel delivery systems. Current specifics are unconfirmed.

3. How does patent expiry affect the market potential?

   • Patent expiry typically opens market for generics, reducing prices and margins but increasing volume.

4. What are the primary regulatory hurdles?

   • Demonstrating safety and efficacy, especially for new formulations or delivery methods, and navigating approval processes in multiple jurisdictions.

5. What is the projected timeline for OCTOCAINE commercialization?

   • Assuming successful development, market entry could occur within 2-5 years, roughly between 2024 and 2027.

---

References:

[1] Grand View Research. (2022). Local Anesthetics Market Size, Share & Trends Analysis Report.
[2] U.S. Food & Drug Administration. (2022). Guidance for Industry on New Drug Approval Process.
[3] MarketsandMarkets. (2022). Local Anesthetics Market by Product Type, Application, and Region—Global Forecast to 2028.
[4] PatentScope. (2023). Patent filings related to local anesthetic formulations.